Obesity is associated with elevated levels of cFGF21, and the expected beneficial effects of FGF21 for improving glucose tolerance and reducing plasma glucose and triglyceride levels are attenuated or even lost in obesity, suggesting the existence of an FGF21-resistant state (84). This evidence concerns the gene FGF21 and obesity disorder.